A5003485279- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Mechanisms and Therapy
- Cancer Cells and Metastasis
- Brain Metastases and Treatment
- Molecular Biology Techniques and Applications
- Cancer Genomics and Diagnostics
- Intraperitoneal and Appendiceal Malignancies
- FOXO transcription factor regulation
- Colorectal Cancer Treatments and Studies
- Palliative Care and End-of-Life Issues
- Endometrial and Cervical Cancer Treatments
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Testicular diseases and treatments
- Hair Growth and Disorders
- Chemotherapy-related skin toxicity
- Lung Cancer Research Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Autophagy in Disease and Therapy
- PI3K/AKT/mTOR signaling in cancer
- Economic and Financial Impacts of Cancer
Istituto Oncologico Veneto
2016-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2024
University of Padua
2019-2021
Abstract Epithelial ovarian cancer (EOC) is one of the most malignant gynecological tumors with a high mortality rate owing to tumor relapse after anticancer therapies. It widely accepted that rare cell population, known as stem cells (CSC), responsible for progression and relapse; intriguingly, these are able survive nutrient starvation (such in vitro culture absence glucose) chemotherapy treatment. Recent data also indicated resistance associated autophagy activation. We thus decided...
Background. We evaluated immunohistochemical AR expression and correlation with prognosis in a large series of homogeneously treated patients primary TNBC. Material methods. Patients diagnosed stage I-III TNBC between 2000 2015 at Istituto Oncologico Veneto who received treatment surgery neoadjuvant and/or adjuvant chemotherapy were included. Whole tissue slides stained for AR. AR-positive was defined as >1% positively tumor cells. Distant-disease-free survival (DDFS) calculated from...
Abstract Receptors tyrosine kinase (RTK) enable normal and tumor cells to perceive adapt stimuli present in the microenvironment. These stimuli, also known as growth factors, are important molecular cues actively supporting cancer stem cell (CSC) self-renewal viability. Since epithelial ovarian (EOC) expression of c-Kit (CD117) has been identified a CSC hallmark, we investigated existence growth-promoting loop between its ligand Stem Cell Factor (SCF). SCF exists soluble or transmembrane...
To explore the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, bevacizumab.A multicenter, phase IV, single arm trial was performed. Patients (FIGO (International Federation of Gynecology Obstetrics) stage IIIB-IV) or recurrent, previously untreated, received carboplatin (AUC (area under curve) 5), paclitaxel (175 mg/m2) plus bevacizumab (15 mg/kg) on day 1 six 3-weekly cycles followed by agent until...
Chemotherapy-induced alopecia (CIA) affects the majority of patients receiving chemotherapy (CT) for early breast cancer. It is a highly distressing side effect CT, with psychological and social impact. Primary aim present analysis was to assess efficacy scalp cooling DigniCap® in preventing CIA. Success rate defined as patients' self-reported hair loss <50% according Dean scale. In this analysis, we reported success at 3 weeks after first CT course last course. Secondary endpoints included...
Background. Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy worldwide. Brain metastasis (BM) quite an uncommon presentation. However, likelihood of central nervous system (CNS) metastasization should be considered in context disseminated disease. The therapeutic management BMs unmet clinical need, to date. Case We identified across different Cancer Centers six cases both BRCA wild-type and BRCA-mutated EOC spreading CNS. They presented either with a single brain...
Abstract Background Trabectedin, in addition to its antiproliferative effect, can modify the tumour microenvironment and this could be synergistic with bevacizumab. The efficacy safety of trabectedin bevacizumab ± carboplatin have never been investigated. Methods In phase 2 study, women progressing between 6 12 months since their last platinum-based therapy were randomised Arm BT: bevacizumab, every 21 days, or BT+C: 28 from cycles 1 6, then as BT. Primary endpoints progression-free survival...
Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy worldwide. Despite latest advances, a major clinical issue in EOC disappointing prognosis related to chemoresistance almost one-third of cases. Drug resistance relies on heterogeneous stem cells (CSCs), endowed with tumor-initiating potential, leading relapse. No biomarkers have been validated yet. Recently, signaling pathways, micro ribonucleic acids (miRNAs), and circulating tumor (CTCs) advocated as putative...
Triple-negative breast cancer (TNBC) poses a challenge due to high metastatic potential and few care options. The successful management of relapsed disease is an unmet clinical need, date. antibody drug conjugate sacituzumab govitecan (SG) has been actual breakthrough in the TNBC (mTNBC) algorithm. Herein, we report case 45-year-old patient, who was referred our centre for hard-to-treat locoregional relapse from TNBC, thus receiving SG third-line setting 15 months. We also discuss...
<h3>Introduction</h3> The use of routine antithrombotic prophylaxis is not recommended for advanced cancer patients receiving chemotherapy. effect bevacizumab-containing therapy on the risk thromboembolic events remains controversial in ovarian patients. We report incidence and prevalence enrolled single arm, phase IV, MITO-16A/MaNGO-OV2A trial. <h3>Methods</h3> In this trial, potential prognostic factors with previously untreated a combination platinum-based chemotherapy bevacizumab were...
254 Background: Early palliative care has been shown to improve patient (pts) and caregiver satisfaction, symptom control, quality of end-of-life care, cost in some cases survival pts with advanced cancer. In accordance ASCO, ESMO AIOM guidelines a Simultaneous Care Clinic (SCC) was set up at Veneto Institute Oncology (IOV) since 2014. the Castelfranco Branch IOV, SCC started January 2022. Methods: Data from all consecutive outpatient patients seen were retrieved prospectively maintained...
Abstract Background: Trastuzumab + pertuzumab taxane and ado-trastuzumab emtansine (T-DM1) are standard first second-line therapies for HER2+ metastatic breast cancer. Lapatinib is approved in combination with capecitabine trastuzumab-resistant patients letrozole hormone receptor positive pts whom endocrine treatment indicated. In Italy, L also trastuzumab receptor-negative pts. There only few data on the activity of lapatinib who received prior /or T-DM1. Methods: We retrospectively...
Abstract Background: The integration of Residual Cancer Burden (RCB) and post-treatment Ki67 (Residual Proliferative [RPCB] index) has been proposed as a stronger predictor long-term outcome in unselected breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NACT), compared to RCB. However, no specific analysis the subgroup with hormone-receptor (HR)-positive/HER2-negative BC is available so far. We investigated prognostic value RPCB an independent cohort (HR) positive/HER2...
<h3>Introduction/Background</h3> poly-ADP ribose polymerase inhibitors (PARPi) are approved as maintenance therapy in epithelial ovarian cancer (EOC) after response to last platinum-based both first line and the platinum-sensitive relapse. Although they have modified clinical practice, few data available on post-progression treatments response. Methodology we evaluated, a real-life population, treatment patterns PARPi therapy, evaluating duration of (DOR) PARPi, progression free survival...